PMC:7172841 / 26171-26460
Annnotations
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T32 | 243-270 | http://purl.obolibrary.org/obo/GO_0050728 | denotes | anti-inflammatory responses |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T187 | 0-289 | Sentence | denotes | These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T822 | 94-103 | DG_39 | denotes | Sarilumab |
| T823 | 121-132 | DG_35 | denotes | Tocilizumab |
| T56935 | 51-55 | PR:000001393 | denotes | inic |
| T72906 | 77-80 | PR:000029150 | denotes | acy |
| T21106 | 84-94 | GO:0010467 | denotes | Anakinra, |
| T43307 | 191-200 | DG_39 | denotes | 298 and E |
| T89983 | 218-229 | DG_35 | denotes | -001039-29) |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1016 | 280-288 | Species | denotes | patients | Tax:9606 |
| 1017 | 94-103 | Chemical | denotes | Sarilumab | MESH:C000592401 |
| 1018 | 105-115 | Chemical | denotes | Siltuximab | MESH:C504234 |
| 1019 | 121-132 | Chemical | denotes | Tocilizumab | MESH:C502936 |